These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28141924)

  • 1. Classics in Chemical Neuroscience: Xanomeline.
    Bender AM; Jones CK; Lindsley CW
    ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Development of Muscarinic Acetylcholine M
    Takai K; Enomoto T
    Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
    Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
    Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
    Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
    ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased Profile of Xanomeline at the Recombinant Human M
    McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
    ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.
    Jakubík J; Tucek S; El-Fakahany EE
    J Pharmacol Exp Ther; 2004 Jan; 308(1):105-10. PubMed ID: 14569060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.
    Thomsen M; Fulton BS; Caine SB
    Psychopharmacology (Berl); 2014 Feb; 231(3):469-79. PubMed ID: 23995301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
    Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
    J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice.
    Woolley ML; Carter HJ; Gartlon JE; Watson JM; Dawson LA
    Eur J Pharmacol; 2009 Jan; 603(1-3):147-9. PubMed ID: 19111716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M
    Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
    Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
    Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
    De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
    Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
    Wang D; Yang L; Su J; Niu Y; Lei X; Xiong J; Cao X; Hu Y; Mei B; Hu JF
    Biochem Biophys Res Commun; 2011 Jul; 410(2):229-34. PubMed ID: 21651893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrine-xanomeline and tacrine-iperoxo hybrid ligands: Synthesis and biological evaluation at acetylcholinesterase and M
    Maspero M; Volpato D; Cirillo D; Yuan Chen N; Messerer R; Sotriffer C; De Amici M; Holzgrabe U; Dallanoce C
    Bioorg Chem; 2020 Mar; 96():103633. PubMed ID: 32032848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of muscarinic M
    Stoll K; Hart R; Lindsley CW; Thomsen M
    Psychopharmacology (Berl); 2018 Mar; 235(3):815-827. PubMed ID: 29250738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
    Paul SM; Yohn SE; Brannan SK; Neugebauer NM; Breier A
    Biol Psychiatry; 2024 Oct; 96(8):627-637. PubMed ID: 38537670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.